117 related articles for article (PubMed ID: 33069923)
1. Activin type IIA decoy receptor and intermittent parathyroid hormone in combination overturns the bone loss in disuse-osteopenic mice.
Brent MB; Lodberg A; Bromer FD; van der Eerden BCJ; Eijken M; Brüel A; Thomsen JS
Bone; 2021 Jan; 142():115692. PubMed ID: 33069923
[TBL] [Abstract][Full Text] [Related]
2. PTH (1-34) and growth hormone in prevention of disuse osteopenia and sarcopenia in rats.
Brent MB; Brüel A; Thomsen JS
Bone; 2018 May; 110():244-253. PubMed ID: 29475111
[TBL] [Abstract][Full Text] [Related]
3. PTH (1-34), but not strontium ranelate counteract loss of trabecular thickness and bone strength in disuse osteopenic rats.
Brüel A; Vegger JB; Raffalt AC; Andersen JE; Thomsen JS
Bone; 2013 Mar; 53(1):51-8. PubMed ID: 23246791
[TBL] [Abstract][Full Text] [Related]
4. A soluble activin type IIA receptor mitigates the loss of femoral neck bone strength and cancellous bone mass in a mouse model of disuse osteopenia.
Lodberg A; Eijken M; van der Eerden BCJ; Okkels MW; Thomsen JS; Brüel A
Bone; 2018 May; 110():326-334. PubMed ID: 29499419
[TBL] [Abstract][Full Text] [Related]
5. Additive effect of PTH (1-34) and zoledronate in the prevention of disuse osteopenia in rats.
Vegger JB; Nielsen ES; Brüel A; Thomsen JS
Bone; 2014 Sep; 66():287-95. PubMed ID: 24970039
[TBL] [Abstract][Full Text] [Related]
6. The Efficacy of PTH and Abaloparatide to Counteract Immobilization-Induced Osteopenia Is in General Similar.
Brent MB; Thomsen JS; Brüel A
Front Endocrinol (Lausanne); 2020; 11():588773. PubMed ID: 33162940
[TBL] [Abstract][Full Text] [Related]
7. Anti-sclerostin antibodies and abaloparatide have additive effects when used as a countermeasure against disuse osteopenia in female rats.
Brent MB; Brüel A; Thomsen JS
Bone; 2022 Jul; 160():116417. PubMed ID: 35398589
[TBL] [Abstract][Full Text] [Related]
8. Disuse-induced loss of bone mineral density and bone strength is attenuated by post-lactational bone gain in NMRI mice.
Sørensen TG; Brent MB; Thomsen JS; Brüel A
Bone; 2020 Feb; 131():115183. PubMed ID: 31794846
[TBL] [Abstract][Full Text] [Related]
9. Rodent model of disuse-induced bone loss by hind limb injection with botulinum toxin A.
Brent MB; Lodberg A; Thomsen JS; Brüel A
MethodsX; 2020; 7():101079. PubMed ID: 33083241
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone mitigates loss of periosteal bone formation and muscle mass in disuse osteopenic rats.
Grubbe MC; Thomsen JS; Nyengaard JR; Duruox M; Brüel A
J Musculoskelet Neuronal Interact; 2014 Dec; 14(4):473-83. PubMed ID: 25524973
[TBL] [Abstract][Full Text] [Related]
11. Bone anabolic effects of separate and combined therapy with growth hormone and parathyroid hormone on femoral neck in aged ovariectomized osteopenic rats.
Wang L; Orhii PB; Banu J; Kalu DN
Mech Ageing Dev; 2001 Jan; 122(1):89-104. PubMed ID: 11163626
[TBL] [Abstract][Full Text] [Related]
12. Androgens have antiresorptive effects on trabecular disuse osteopenia independent from muscle atrophy.
Laurent MR; Jardí F; Dubois V; Schollaert D; Khalil R; Gielen E; Carmeliet G; Claessens F; Vanderschueren D
Bone; 2016 Dec; 93():33-42. PubMed ID: 27622887
[TBL] [Abstract][Full Text] [Related]
13. RAGE supports parathyroid hormone-induced gains in femoral trabecular bone.
Philip BK; Childress PJ; Robling AG; Heller A; Nawroth PP; Bierhaus A; Bidwell JP
Am J Physiol Endocrinol Metab; 2010 Mar; 298(3):E714-25. PubMed ID: 20028966
[TBL] [Abstract][Full Text] [Related]
14. Pantoprazole, a proton pump inhibitor, does not prevent botulinum toxin induced disuse osteopenia in mice.
Vegger JB; Brüel A; Thomsen JS
J Musculoskelet Neuronal Interact; 2017 Sep; 17(3):162-175. PubMed ID: 28860418
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Normobaric Intermittent Hypoxia Therapy on Bone in Normal and Disuse Osteopenic Mice.
Bromer FD; Brent MB; Pedersen M; Thomsen JS; Brüel A; Foldager CB
High Alt Med Biol; 2021 Jun; 22(2):225-234. PubMed ID: 33769867
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment with a beta-blocker and intermittent PTH improves bone mass and microarchitecture in ovariectomized mice.
Pierroz DD; Bouxsein ML; Rizzoli R; Ferrari SL
Bone; 2006 Aug; 39(2):260-7. PubMed ID: 16531131
[TBL] [Abstract][Full Text] [Related]
17. Activin receptor signaling: a potential therapeutic target for osteoporosis.
Lotinun S; Pearsall RS; Horne WC; Baron R
Curr Mol Pharmacol; 2012 Jun; 5(2):195-204. PubMed ID: 21787285
[TBL] [Abstract][Full Text] [Related]
18. Low-dose PTH increases osteoblast activity via decreased Mef2c/Sost in senescent osteopenic mice.
Saidak Z; Le Henaff C; Azzi S; Marty C; Marie PJ
J Endocrinol; 2014 Oct; 223(1):25-33. PubMed ID: 25056116
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of the bone metabolic response to dried plum supplementation and PTH treatment in adult, osteopenic ovariectomized rat.
Smith BJ; Bu SY; Wang Y; Rendina E; Lim YF; Marlow D; Clarke SL; Cullen DM; Lucas EA
Bone; 2014 Jan; 58():151-9. PubMed ID: 24125756
[TBL] [Abstract][Full Text] [Related]
20. Intermittent treatment with human parathyroid hormone (hPTH[1-34]) increased trabecular bone volume but not connectivity in osteopenic rats.
Lane NE; Thompson JM; Strewler GJ; Kinney JH
J Bone Miner Res; 1995 Oct; 10(10):1470-7. PubMed ID: 8686502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
